Insmed (NASDAQ:INSM – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Profitability
This table compares Insmed and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -39.85% | -96.38% | -32.55% |
| Syndax Pharmaceuticals | -72.32% | -804.38% | -34.93% |
Valuation and Earnings
This table compares Insmed and Syndax Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insmed | $606.42 million | 44.45 | -$1.28 billion | ($2.82) | -43.57 |
| Syndax Pharmaceuticals | $172.35 million | 4.77 | -$285.42 million | ($2.36) | -3.87 |
Syndax Pharmaceuticals has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Insmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Insmed and Syndax Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
Insmed presently has a consensus target price of $196.52, suggesting a potential upside of 59.93%. Syndax Pharmaceuticals has a consensus target price of $41.60, suggesting a potential upside of 355.64%. Given Syndax Pharmaceuticals’ higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Insmed.
Summary
Insmed beats Syndax Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
